Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5116276 | 0.77 | ALDH1A1 (0.38) | ALDH1A1GAASLC6A4TSHRKMT2A | |
| SCHEMBL13384870 | 0.74 | SLC6A4 (0.41) | ALDH1A1GAASLC6A4TSHRKMT2A | |
| SCHEMBL5115915 | 0.71 | SLC6A4 (0.34) | ALDH1A1GAASLC6A4TSHR | |
| SCHEMBL8262524 | 0.69 | — | — | |
| SCHEMBL28240784 | 0.68 | SLC6A4 (0.37) | ALDH1A1GAASLC6A4TSHRKMT2A | |
| SCHEMBL28250365 | 0.67 | ALDH1A1 (0.37) | ALDH1A1GAATSHRKMT2APOLB | |
| SCHEMBL28256836 | 0.67 | ALDH1A1 (0.37) | ALDH1A1GAATSHRKMT2AHPGD | |
| SCHEMBL6846735 | 0.66 | — | — | |
| SCHEMBL6857135 | 0.66 | ALDH1A1 (0.39) | ALDH1A1GAATSHRKMT2AHPGD | |
| SCHEMBL2856264 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608617-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2013-01-09 | — | — | EP | disclosed |
| US-7378447-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20060178438-A1 | Muscarinic agonists | ELI LILLY AND COMPANY (IN) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178438-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | ALDH1A1 709/4885GAA 4321/4885SLC6A4 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.